Dow Corning Healthcare division responds to global flu outbreak
In response to the urgent needs of pharmaceutical customers developing flu vaccines and anti-viral drugs used to battle potential pandemics, Dow Corning has ramped up its silicone tubing production capabilities. Dow Corning is able to produce additional pharmaceutical grade silicone tubing designed for critical fluid transport and filling applications necessary for drug and vaccine production in order to meet the increased demand.
“As the only global silicone manufacturer involved in each step of the manufacturing process -from processing the raw materials to producing extruded and molded pharmaceutical grade silicone - Dow Corning is in a unique position to rapidly provide reliable, proven tubing,” said Carol Pudnos, Dow Corning global Healthcare industry director.
Dow Corning has manufactured products used to meet the stringent requirements of ultra-pure fluid handling for vaccine production for nearly 50 years. The company’s silicone tubing and fabricated tubing assemblies are produced with Dow Corning Silastic® BioMedical Grade Elastomers at Dow Corning’s FDA-registered Health Industries Materials Site in Hemlock, Michigan.
Visit us to learn more about Dow Corning’s innovative Healthcare solutions.
About Dow Corning
Dow Corning provides performance-enhancing solutions to serve the diverse needs of more than 25,000 customers worldwide. A global leader in silicones, silicon-based technology and innovation, Dow Corning offers more than 7,000 products and services via the company’s Dow Corning® and XIAMETER® brands. Dow Corning is a joint venture equally owned by The Dow Chemical Company and Corning, Incorporated. More than half of Dow Corning’s annual sales are outside the United States.
This news content was configured by WebWire editorial staff. Linking is permitted.
News Release Distribution and Press Release Distribution Services Provided by WebWire.